Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betaxolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levobetaxolol SCHEMBL42795 | 1.00 | LMNA (1.00) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL4997902 | 0.99 | ADRB1 (1.00) | LMNAADRB1ADRB2GAABLM | |
| Levobetaxolol SCHEMBL23532 | 0.99 | ADRB1 (1.00) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL6512495 | 0.99 | ADRB1 (1.00) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL23530 | 0.99 | ADRB1 (1.00) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL23531 | 0.99 | ADRB1 (1.00) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL26664826 | 0.98 | ADRB1 (0.98) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL26664823 | 0.98 | ADRB1 (0.98) | LMNAADRB1ADRB2GAABLM | |
| Levobetaxolol SCHEMBL1649403 | 0.97 | ADRB1 (0.96) | LMNAADRB1ADRB2GAABLM | |
| Betaxolol SCHEMBL613385 | 0.97 | ADRB1 (0.96) | LMNAADRB1ADRB2GAABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6485 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | claimed |
| CN-119405621-A | Drug-loaded polyacrylic resin nanoparticle as well as preparation method and application thereof | 广东药科大学 | 2025-02-11 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-114796219-B | Compound pharmaceutical composition for treating glaucoma and application thereof | 沈阳药科大学 | 2024-08-20 | — | — | CN | claimed |
| CN-118490691-A | Use of adenosine A2A receptor antagonists in the treatment and prevention of glaucoma | 温州医科大学附属眼视光医院 | 2024-08-16 | — | — | CN | claimed |
| CN-118403017-A | Strong-hydrophobicity slow-release microsphere and preparation method and application thereof | 广东药科大学 | 2024-07-30 | — | — | CN | claimed |
| US-20240033258-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE (US) | 2024-02-01 | — | — | US | claimed |
| EP-0347987-A2 | Tripeptide renin inhibitors with N-terminal carbamoyl or acyl groups | MERCK & CO. INC. (US) | 1989-12-27 | — | — | EP | claimed |
| EP-0314239-A2 | Tripeptide renin inhibitors with N-terminal ureido or sulfamido groups | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | claimed |
| EP-0312291-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312158-A2 | Tetrapeptide renin inhibitors having novel c-terminal amino acid amide | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0286903-A1 | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1988-10-19 | — | — | EP | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |